Clinical Trials Logo

Chondrosarcomas clinical trials

View clinical trials related to Chondrosarcomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT02389244 Recruiting - Chondrosarcomas Clinical Trials

A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

REGOBONE
Start date: September 2014
Phase: Phase 2
Study type: Interventional

INDICATION: Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas and chordomas and either bone or soft tissue metastatic CIC-rearranged sarcomas

NCT ID: NCT01449149 Active, not recruiting - Chondrosarcomas Clinical Trials

Proton Radiation for Chordomas and Chondrosarcomas

Start date: March 2010
Phase: N/A
Study type: Interventional

The objectives of this study are 1) To evaluate the feasibility and acute side effects of proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and long term side effects of proton beam radiation for treatment of chordomas and chondrosarcomas.

NCT ID: NCT00797602 Completed - Chondrosarcomas Clinical Trials

Proton Therapy for Chordomas and/or Chondrosarcomas

CH01
Start date: January 2007
Phase: N/A
Study type: Observational

The purpose of this study is to collect information from medical records to see what effects proton beam radiation has on cancer and analyze possible side effects.

NCT ID: NCT00401388 Completed - Chondrosarcomas Clinical Trials

A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

Start date: November 2006
Phase: Phase 2
Study type: Interventional

This is a phase II study of perifosine in patients with chondrosarcomas, alveolar soft part sarcomas and extra-skeletal myxoid chondrosarcomas. Patients will receive perifosine 100 mg orally qhs with food until disease progression. The goals of this study include: - In this study a daily dose of perifosine previously determined to be relatively non-toxic will be evaluated in patients with chondrosarcomas, alveolar soft part sarcomas and extra-skeletal myxoid chondrosarcomas. - Response to therapy will be based on regression of measurable disease according to Choi criteria. Time to progression and duration of stable disease will be measured as secondary endpoints of the study.